Adage Capital Partners Portfolio holdings
AUM
$59.3B
This Quarter Return
+27.25%
1 Year Return
+26.26%
3 Year Return
+130.73%
5 Year Return
+248.99%
10 Year Return
+658.76%
AUM
$39.1B
AUM Growth
+$39.1B
(+17%)
Cap. Flow
-$1.07B
Cap. Flow
% of AUM
-2.74%
Top 10 Holdings %
Top 10 Hldgs %
25.2%
Holding
834
New
111
Increased
264
Reduced
307
Closed
110
Top Buys
| 1 |
Royalty Pharma
RPRX
|
$2.23B |
| 2 |
Otis Worldwide
OTIS
|
$211M |
| 3 |
Burlington
BURL
|
$200M |
| 4 |
AbbVie
ABBV
|
$199M |
| 5 |
Wayfair
W
|
$190M |
Top Sells
| 1 |
AGN
Allergan plc
AGN
|
$1.66B |
| 2 |
Lockheed Martin
LMT
|
$327M |
| 3 |
Johnson & Johnson
JNJ
|
$253M |
| 4 |
Pfizer
PFE
|
$153M |
| 5 |
Target
TGT
|
$148M |
Sector Composition
| 1 | Technology | 21.53% |
| 2 | Healthcare | 19.78% |
| 3 | Consumer Discretionary | 13.1% |
| 4 | Financials | 11.32% |
| 5 | Industrials | 8.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Booking.com
BKNG
$181B
| $75.2M | 0.19% |
47,200
-500
| -1% | -$796K |
|
127
Freeport-McMoran
FCX
$63.7B
| $74.6M | 0.19% |
6,445,000
+4,775,000
| +286% | +$55.2M |
|
128
Sherwin-Williams
SHW
$91.2B
| $74.3M | 0.19% |
128,660
-186,092
| -59% | -$108M |
|
129
Honeywell
HON
$139B
| $73.8M | 0.19% |
510,300
-938,675
| -65% | -$136M |
|
130
Colgate-Palmolive
CL
$67.9B
| $72.5M | 0.19% |
989,120
+11,900
| +1% | +$872K |
|
131
Kimberly-Clark
KMB
$42.8B
| $72.4M | 0.19% |
512,323
-199,632
| -28% | -$28.2M |
|
132
Equinix
EQIX
$76.9B
| $71.8M | 0.18% |
102,268
+5,100
| +5% | +$3.58M |
|
133
L3Harris
LHX
$51.9B
| $71.3M | 0.18% |
420,325
+206,596
| +97% | +$35.1M |
|
134
Saic
SAIC
$5.52B
| $71.2M | 0.18% |
916,588
+370,074
| +68% | +$28.7M |
|
135
Advanced Micro Devices
AMD
$264B
| $71M | 0.18% |
1,348,800
-194,100
| -13% | -$10.2M |
|
136
Owens Corning
OC
$12.6B
| $70.9M | 0.18% |
1,271,731
+202,864
| +19% | +$11.3M |
|
137
Hillenbrand
HI
$1.79B
| $70.7M | 0.18% |
2,610,735
+953,133
| +58% | +$25.8M |
|
|
138
Target
TGT
$43.6B
| $69.4M | 0.18% |
579,008
-1,237,961
| -68% | -$148M |
|
|
MNTA
139
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $68.2M | 0.17% |
2,050,000
-70,000
| -3% | -$2.33M |
|
140
Stryker
SYK
$150B
| $67.3M | 0.17% |
373,274
-145,700
| -28% | -$26.3M |
|
141
Olin
OLN
$2.71B
| $66.9M | 0.17% |
5,819,782
-1,350,000
| -19% | -$15.5M |
|
142
Arthur J. Gallagher & Co
AJG
$77.6B
| $66.4M | 0.17% |
681,003
-199,697
| -23% | -$19.5M |
|
143
CF Industries
CF
$14B
| $66M | 0.17% |
2,345,542
-904,100
| -28% | -$25.4M |
|
144
Zoetis
ZTS
$69.3B
| $65.8M | 0.17% |
480,389
-8,900
| -2% | -$1.22M |
|
145
Dover
DOV
$24.5B
| $65.6M | 0.17% |
679,484
-1,094,065
| -62% | -$106M |
|
146
Louisiana-Pacific
LPX
$6.62B
| $65.2M | 0.17% |
2,541,730
-1,256,986
| -33% | -$32.2M |
|
147
CME Group
CME
$96B
| $64.7M | 0.17% |
398,031
+5,400
| +1% | +$878K |
|
148
Goldman Sachs
GS
$226B
| $63.2M | 0.16% |
319,800
-64,400
| -17% | -$12.7M |
|
149
Illumina
ILMN
$15.8B
| $63.1M | 0.16% |
170,277
+97,105
| +133% | +$36M |
|
150
Karyopharm Therapeutics
KPTI
$61.7M
| $61.5M | 0.16% |
3,248,739
-474,793
| -13% | -$8.99M |
|